Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Continued Access to Darunavir/Ritonavir in HIV-1
NCT01281813Phase 3Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Aug 2011
- Primary completion
- Jul 2021
- Modality
- Small Molecules
- Countries
- 8
01
Overview
A Phase 3 trial of darunavir in human immunodeficiency virus type 1 infection (HIV-1), sponsored by Janssen Pharmaceutical. Started Aug 2011; status: completed.
02
Drugs
darunavir
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT01281813.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01281813.